Richard Staub III Named President of R&D Solutions at IQVIA

IQVIA has appointed Richard Staub III, currently senior advisor to the board chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit.
 
Staub is an experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. He previously served as IQVIA’s R&DS business unit president from 2016 to 2022 and under his leadership, the unit accelerated its growth, recorded consecutive years of record-breaking backlog, posted industry-leading book to bill ratios and significantly increased R&DS revenues. During his tenure Staub supervised the rapid expansion of IQVIA’s clinical research capabilities and, critically, he successfully led this business unit through the unprecedented challenges of the COVID-19 global pandemic.
 
In his role as senior advisor to IQVIA’s board chairman and CEO, Staub worked closely with the R&DS team and was instrumental in R&DS’ continued success. He had responsibility for key customer relationships, provided leadership on critical business issues and continued to guide the company’s overall strategic direction.

Before IQVIA, Staub was president of Novella Clinical, a specialty clinical research organization acquired by Quintiles in 2013. Joining Novella in 2004, he served as president and CEO for five years. Under his leadership, Novella became a distinctively agile, results oriented CRO in the highly complex and fast-growing areas of specialty pharmaceuticals and medical technology. Before he worked for Novella, Staub was senior vice president of global business development for one of the world’s largest CROs. His pharmaceutical industry career began at Zeneca Pharmaceuticals, where he was given increasing responsibilities as a medical and hospital sales representative, cardiovascular portfolio analyst, and marketing manager.

Staub earned a bachelor’s degree in economics from the University of North Carolina at Chapel Hill.
 
Staub’s predecessor, Costa Panagos, is retiring from IQVIA after a 24 years. He held several positions at the firm, including most recently the R&DS business unit leadership role since 2022. 
 
IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence delivers powerful insights with speed and agility—enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.